Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43707

UPID:
ACTN4_HUMAN

ALTERNATIVE NAMES:
Non-muscle alpha-actinin 4

ALTERNATIVE UPACC:
O43707; A4K467; D6PXK4; O76048

BACKGROUND:
The protein Alpha-actinin-4 is crucial for F-actin bundling and is likely involved in intracellular structure anchoring. It plays a significant role in epithelial cell tight junction assembly and vesicular trafficking, mediated by its association with the CART complex and interaction with MICALL2. Alpha-actinin-4 also functions as a transcriptional coactivator, enhancing PPARG and RARA-mediated transcription.

THERAPEUTIC SIGNIFICANCE:
Given its association with Focal segmental glomerulosclerosis 1, a condition that severely impairs renal function, Alpha-actinin-4 represents a key target for developing treatments aimed at halting or reversing kidney disease progression.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.